CredoScientia - Bibliothèque

Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.

BACKGROUND/AIM: Mutant BRAF V600E colorectal cancer accounts for 5% of metastatic colorectal cancers, and it has a poor response to systemic chemotherapy and a poor prognosis. However, combination tre…

Thérapies de Conversion

Kawata, A., Miyamoto, Y., Fukubayashi, K., Horio, T., Miyamoto, H., Ogawa, K., Ouchi, M., Tanaka, Y., & Baba, H. (2023). Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory V600E-mutated Colorectal Cancer With Para-aortic Lymph Node Metastases.. In Vivo, 37(4), 1797-1801. https://doi.org/10.21873/invivo.13269

01/01/2023 Lire →

Safety and efficacy of laparoscopic digestive tract nutrition reconstruction combined with conversion therapy for patients with unresectable and obstructive gastric cancer.

BACKGROUND: To explore the safety, efficacy, and survival benefits of laparoscopic digestive tract nutrition reconstruction (LDTNR) combined with conversion therapy in patients with unresectable gastr…

Thérapies de Conversion

Ye, R., Wang, C., Hu, B., & Guan, G. (2023). Safety and efficacy of laparoscopic digestive tract nutrition reconstruction combined with conversion therapy for patients with unresectable and obstructive gastric cancer.. Front Oncol, 13, 1175580. https://doi.org/10.3389/fonc.2023.1175580

01/01/2023 Lire →

Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.

Thérapies de Conversion

Zhang, E. L. (2023). Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.. Front Immunol, 14, 1218845. https://doi.org/10.3389/fimmu.2023.1218845

01/01/2023 Lire →

Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

[This corrects the article DOI: 10.3389/fimmu.2023.1151967.].

Thérapies de Conversion

Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., & Ma, G. (2023). Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.. Front Immunol, 14, 1219757. https://doi.org/10.3389/fimmu.2023.1219757

01/01/2023 Lire →

The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.

PURPOSE: To explore the safety and efficacy of lenvatinib in combination with trans-arterial chemoembolization (TACE) and programmed death receptor 1 (PD-1) antibody in the treatment of unresectable r…

Thérapies de Conversion

Mu, C., Shen, J., Zhu, X., Peng, W., Zhang, X., & Wen, T. (2023). The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.. Front Oncol, 13, 1096955. https://doi.org/10.3389/fonc.2023.1096955

01/01/2023 Lire →

Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two

Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can und…

Thérapies de Conversion

Ning, C., Liu, G., Zhang, J., Yang, X., Xu, Y., & Zhao, H. (2023). Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two. Front Immunol, 14, 1159885. https://doi.org/10.3389/fimmu.2023.1159885

01/01/2023 Lire →

The role of F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

PURPOSE: To investigate the diagnostic value of F-fluorodeoxyglucose positron emission tomography (F-FDG PET), as an imaging biomarker, for predicting pathological response and prognosis of unresectab…

Thérapies de Conversion

Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., & Ma, G. (2023). The role of F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.. Front Immunol, 14, 1151967. https://doi.org/10.3389/fimmu.2023.1151967

01/01/2023 Lire →

Gender and sexuality in mental health: perspectives on lesbians, gays, bisexuals, and transgender (LGBT) rights and mental health in the ASEAN region.

This perspective piece focuses on and analyzes several lesbians, gays, bisexuals, and transgender (LGBT) individuals' rights and their limitations in the Association of Southeast Asian Nations (ASEAN)…

Thérapies de Conversion

Alibudbud, R. (2023). Gender and sexuality in mental health: perspectives on lesbians, gays, bisexuals, and transgender (LGBT) rights and mental health in the ASEAN region.. Front Sociol, 8, 1174488. https://doi.org/10.3389/fsoc.2023.1174488

01/01/2023 Lire →

Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnos…

Thérapies de Conversion

Zhang, Z., & Zhang, E. (2023). Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.. Front Immunol, 14, 1073531. https://doi.org/10.3389/fimmu.2023.1073531

01/01/2023 Lire →

Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.

Thérapies de Conversion

Andrade, E. R. (2023). Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.. Int J Radiat Biol, 99(11), 1800-1801. https://doi.org/10.1080/09553002.2023.2211147

01/01/2023 Lire →

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.

PURPOSE: The purpose of this study was to investigate the triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy as a conversion therapy for initially unresectable h…

Thérapies de Conversion

Gan, L., Lang, M., Tian, X., Ren, S., Li, G., Liu, Y., Han, R., Zhu, K., Li, H., Wu, Q., Cui, Y., Zhang, W., Fang, F., Li, Q., & Song, T. (2023). A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 673-686. https://doi.org/10.2147/JHC.S404675

01/01/2023 Lire →

The Current Status of Sociopolitical and Legal Issues Faced by Lesbian, Gay, Bisexual, Transgender, Queer, and Questioning Youth.

BACKGROUND: Adolescents today have unprecedented and uninterrupted access to news and current events through broadcast and social media. Lesbian, gay, bisexual, transgender, queer, and questioning (LG…

Thérapies de Conversion

Ramos, N., Burgess, A., & Ollen, E. (2023). The Current Status of Sociopolitical and Legal Issues Faced by Lesbian, Gay, Bisexual, Transgender, Queer, and Questioning Youth.. Adolesc Psychiatry (Hilversum), 12(3), 180-195. https://doi.org/10.2174/2210676611666211105120645

01/01/2023 Lire →